{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:05:46Z","timestamp":1771538746991,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic sclerosis (SSc) patients often need immunosuppressive medication (IS) for disease control. If SSc is progressive despite IS, autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for selected SSc patients. aHSCT is effective with good available evidence, but not all patients achieve a treatment-free remission after aHSCT. Thus far, data about the need of IS after aHSCT in SSc is not published. The aim of this study was to investigate the use of IS after aHSCT, its efficacy, and the occurrence of severe adverse events (SAEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-seven patients with SSc who had undergone aHSCT were included in this single-center retrospective cohort study. Clinical data, including IS, SAEs, and lung function data, were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen of 27 (59.3%) patients received IS after aHSCT. Methotrexate, rituximab, mycophenolate, cyclophosphamide, and hydroxychloroquine were most commonly used. The main reason for starting IS was SSc progress. Nine patients received rituximab after aHSCT and showed an improvement in modified Rodnan skin score and a stabilization of lung function 2 years after rituximab. SAEs in patients with IS after aHSCT (50.0%) were not more common than in patients without IS (54.6%). SAEs were mostly due to SSc progress, secondary autoimmune diseases, or infections. Two deaths after aHSCT were transplantation related and three during long-term follow-up due to pulmonary arterial hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Disease progression and secondary autoimmune diseases may necessitate IS after aHSCT in SSc. Rituximab seems to be an efficacious treatment option in this setting. Long-term data on the safety of aHSCT is reassuring.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.817893","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T07:26:46Z","timestamp":1642404406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients\u2014High Efficacy of Rituximab"],"prefix":"10.3389","volume":"12","author":[{"given":"Michael","family":"Gernert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Christina","family":"Schwaneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic Sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR Recommendations for the Treatment of Systemic Sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A Randomized, Controlled Trial of Methotrexate Versus Placebo in Early Diffuse Scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120","article-title":"Scleroderma Lung Study Research Group.Cyclophosphamide Versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Sclerodema Lung Study II Investigators. Mycophenolate Mofetil Versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Randomised Controlled, Double-Blind, Parallel Group Trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A Multicenter, Open-Label, Comparative Study of B-Cell Depletion Therapy With Rituximab for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Arthritis Rheum"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and Efficacy of Rituximab in Systemic Sclerosis (DESIRES): A Double Blind, Investigator-Initiated, Randomized, Placebo Controlled Trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668","article-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous Non-Myeloablativehaemopoietic Stem-Cell Transplantation Compared With Pulse Cyclophosphamide Once Per Month for Systemic Sclerosis (ASSIST): An Open-Label, Randomised Phase 2 Trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368","article-title":"EBMT\/EULAR Scleroderma Study Group. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial","volume":"311","author":"Van Laar","year":"2014","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","article-title":"SCOT Study Investigators. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"65","author":"Van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-019-1889-8","article-title":"Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Induces Long-Lasting Changes in B Cell Homeostasis Toward an Anti-Inflammatory B Cell Cytokine Pattern","volume":"21","author":"Gernert","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-020-02255-3","article-title":"Low B Cell Counts as Risk Factor for Infectious Complications in Systemic Sclerosis After Autologous Hematopoietic Stem Cell Transplantation","volume":"22","author":"Gernert","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B17","first-page":"S","article-title":"ANCA-Positive Vasculitis as a Secondary Autoimmune Disease After Autologous Stem Cell Transplantation for Systemic Sclerosis: A Case Report","volume":"32","author":"Schmalzing","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Resetting the Immune System With Immunoablation and Autologous Haematopoietic Stem Cell Transplantation in Autoimmune Diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-Lived Autoreactive Plasma Cells Drive Persistent Autoimmune Inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22019","article-title":"Regeneration of B Cell Subsets After Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 Therapy in Patients With Rheumatoid Arthritis: Predictors of Response and B Cell Subset Regeneration After Repeated Treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-Term Follow-Up Results After Autologous Haematopoietic Stem Cell Transplantation for Severe Systemic Sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13147","article-title":"Sustained Remission in Multiple Sclerosis After Hematopoietic Stem Cell Transplantation","volume":"140","author":"Tolf","year":"2019","journal-title":"Acta Neurol Scand"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.817893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T07:26:50Z","timestamp":1642404410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.817893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2021.817893"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.817893","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"817893"}}